Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail targets brain tumors in lung cancer patients

NCT ID NCT06822543

Recruiting now Disease control Sponsor: Latin American Cooperative Oncology Group Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 17, 2026 · Updated 28 times

Summary

This study tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) in people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for these brain tumors. The goal is to see if the treatment can shrink or control the brain tumors. About 46 adults will take part, receiving the drugs every three weeks for four cycles, then a two-drug maintenance therapy until the disease gets worse or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • FUNFARME - Hospital de Base de São José do Rio Preto

    RECRUITING

    São José do Rio Preto, São Paulo, 15.090-000, Brazil

    Contact

Conditions

Explore the condition pages connected to this study.

BRAIN METASTASES LUNG CANCER NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER